Clinical Trials Logo

Unfractionated Heparin Treatment clinical trials

View clinical trials related to Unfractionated Heparin Treatment.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04700670 Completed - Clinical trials for Unfractionated Heparin Treatment

Evaluation of the Effect of Dextran Sulphate on Anti-Xa Activities Measured

DEXHEP
Start date: January 16, 2020
Phase:
Study type: Observational

The measurement of anti-Xa activity is classically used for the dose adjustement of unfractionated heparin (UFH) treatment and to monitor reversal of UFH by protamine during cardiac surgery with cardiopulmonary bypass (CPB). Three categories of reagents are currently available in France for the measurement of anti-Xa activity: antithrombin-containing reagents (very little used), antithrombin-free reagents and antithrombin-free reagents with dextran sulphate. Significant differences in anti-Xa results based on the reagents used were described, particularly after protamine neutralization in CPB. Indeed, dextran sulphate, contained in some reagents, could dissociate the heparin/protamine complex contributing to the higher levels of anti-Xa with these reagents. The differences observed in these patients are likely related to the presence of platelet factor 4 (PF4) in the samples from either PF4 present in vivo in patients or released in vitro after blood collection. These differences may lead to different therapeutic attitudes, including the re-administration of protamine to neutralize heparin at the end of CBP